Checkpoint Inhibition Reduces the Threshold for Drug-Specific T-Cell Priming and Increases the Incidence of Sulfasalazine Hypersensitivity

An emerging clinical issue associated with immune-oncology agents is the collateral effects on the tolerability of concomitant medications. One report of this phenomenon was the increased incidence of hypersensitivity reactions observed in patients receiving concurrent immune checkpoint inhibitors (...

Descripción completa

Detalles Bibliográficos
Autores principales: Hammond, Sean, Olsson-Brown, Anna, Grice, Sophie, Gibson, Andrew, Gardner, Joshua, Castrejón-Flores, Jose Luis, Jolly, Carol, Fisher, Benjamin Alexis, Steven, Neil, Betts, Catherine, Pirmohamed, Munir, Meng, Xiaoli, Naisbitt, Dean John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Immunotoxicology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883351/
https://www.ncbi.nlm.nih.gov/pubmed/34850240
http://dx.doi.org/10.1093/toxsci/kfab144

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883351/
https://www.ncbi.nlm.nih.gov/pubmed/34850240
http://dx.doi.org/10.1093/toxsci/kfab144

Ejemplares similares